Adaptive Biotechnologies holder plans 100K share sale

Harlan Robins submitted a Rule 144 notice to sell 10,000 shares of Common Stock on 04/08/2026.

Rhea-AI Filing Summary

Harlan Robins submitted a Rule 144 notice to sell 10,000 shares of Common Stock on 04/08/2026.

The filing also lists recent compensatory issuances: 47,504, 41,246, and 11,250 shares were recorded as "Acquired as compensation -- Performance Awards" on 03/07/2026. A header line shows 160,044,392 shares with an associated date of 06/15/2026 as a contextual figure.

Insights

Securities Compliance Attorney

Notice filed under Rule 144 reporting a sale of 10,000 shares by Harlan Robins.

Rule 144 notices are procedural disclosures of intended or completed sales by affiliates or holders relying on the exemption; the filing records a 10,000-share sale dated 04/08/2026. The document also documents compensatory awards dated 03/07/2026, which may affect available resale limitations.

The practical compliance issues are timing and holding-period requirements; subsequent public filings or broker reports will show whether the sale occurred in compliance with Rule 144 conditions.

Equity Capital Markets Analyst

Small-volume Rule 144 notice; compensatory grants noted the prior month.

The 10,000-share listed sale is modest relative to the header figure of 160,044,392 shares shown with date 06/15/2026. The filing also records three compensatory issuances on 03/07/2026 totaling 99,000 shares across listed awards (47,504; 41,246; 11,250).

On its face, this is routine disclosure; trading impact depends on execution details and whether the sale was completed under Rule 144 conditions.

Key Figures

Shares reported sold: 10,000 shares Performance award: 47,504 shares Performance award: 41,246 shares +2 more

5 metrics

Shares reported sold 10,000 shares Sale date 04/08/2026

Performance award 47,504 shares Acquired as compensation — Performance Awards on 03/07/2026

Performance award 41,246 shares Acquired as compensation — Performance Awards on 03/07/2026

Performance award 11,250 shares Acquired as compensation — Performance Awards on 03/07/2026

Contextual company share count 160,044,392 shares Associated date 06/15/2026 (header line in excerpt)

Key Terms

Rule 144, Acquired as compensation -- Performance Awards, Common Stock, Issuer

4 terms

Rule 144 regulatory

"Securities Sold During The Past 3 Months"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Acquired as compensation -- Performance Awards financial

"03/07/2026 | Acquired as compensation -- Performance Awards"

Common Stock financial

"Common Stock | Goldman Sachs & Co. LLC"

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

Issuer legal

"Acquired as compensation -- Performance Awards | The Issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the ADPT Form 144 filed by Harlan Robins report?

The filing reports a Rule 144 notice for 10,000 shares of Common Stock dated 04/08/2026. It also lists compensatory awards of 47,504, 41,246, and 11,250 shares dated 03/07/2026 as context.

Does the Form 144 disclose when the compensatory shares were issued for ADPT?

Yes. The compensatory shares are recorded as "Acquired as compensation -- Performance Awards" with an effective date of 03/07/2026 for the listed award amounts of 47,504, 41,246, and 11,250 shares.

How large is the reported sale relative to the company's listed share count?

The reported sale is 10,000 shares on 04/08/2026. The header shows 160,044,392 shares with date 06/15/2026, which appears as a contextual company-level figure in the excerpt.

Does the Form 144 indicate whether the 10,000-share sale was completed?

The filing lists the sale date as 04/08/2026 for 10,000 shares. The document excerpt does not provide further confirmation of settlement details or cash‑flow recipients.

What type of securities are noted in the ADPT excerpt?

The excerpt references Common Stock throughout, including compensatory "Performance Awards" and the listed 10,000-share sale under Rule 144.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/15/2026 - 06:10 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001780851
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Adaptive Biotechnologies Corporation
SEC File Number	001-38957
Address of Issuer	1165 Eastlake Avenue East Seattle WASHINGTON 98109
Phone	1-206-659-0067
Name of Person for Whose Account the Securities are To Be Sold	Harlan Robins
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common Stock	Goldman Sachs & Co. LLC 200 West Street New York NY 10282	100000	1746000	160044392	06/15/2026	NASD

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common Stock	03/07/2026	Acquired as compensation -- Performance Awards	The Issuer			47504	03/07/2026	Compensation
Common Stock	03/07/2026	Acquired as compensation -- Performance Awards	The Issuer			41246	03/07/2026	Compensation
Common Stock	03/07/2026	Acquired as compensation -- Performance Awards	The Issuer			11250	03/07/2026	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Harlan Robins 1165 Eastlake Avenue East Seattle WA 98109	Common Stock	04/08/2026	10000	148323.94

144: Remarks and Signature

Remarks	The sales of shares set forth herein are made in connection with a selling plan dated 3/13/2026, that is intended to comply with Rule 10b501(c).
Date of Notice	06/15/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	03/13/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Goldman Sachs & Co. LLC on behalf of Harlan Robins
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)